
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech concluded the third quarter of 2025 with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables, providing the company with substantial financial flexibility to support its research and development initiatives. The progress of its oncology pipeline, especially the upcoming global Phase 3 DYNASTY-Breast02 trial for BNT323, indicates a positive trajectory for its cancer therapeutics segment. Additionally, the improvements in immune responses demonstrated by its adapted COVID-19 vaccine highlight BioNTech's commitment to innovation in both oncology and infectious disease therapies, underscoring the company's potential for sustained growth.
Bears say
BioNTech faces significant risks that contribute to a negative outlook, including the possibility of negative clinical data across multiple oncology candidates, which could hinder their market acceptance and development timelines. The projected full-year net loss per diluted share of €3.99 for 2025, coupled with an already recorded net loss of €0.12 per diluted share for 3Q25, indicates ongoing financial challenges that may deter investor confidence. Furthermore, changing dynamics in the COVID-19 vaccine market, particularly with increased regulatory scrutiny in the U.S., may overshadow the company's oncology portfolio and further complicate its financial recovery.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares